Precision BioSciences (NASDAQ:DTIL) Stock Rating Lowered by Zacks Investment Research
According to Zacks, “Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. “
A number of other analysts also recently issued reports on DTIL. BTIG Research started coverage on shares of Precision BioSciences in a report on Friday, August 9th. They issued a buy rating and a $22.00 price objective on the stock. HC Wainwright restated a buy rating and set a $21.00 target price on shares of Precision BioSciences in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $21.17.
Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.15. Precision BioSciences had a negative return on equity of 78.51% and a negative net margin of 423.14%. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $5.25 million. Sell-side analysts expect that Precision BioSciences will post -1.42 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of DTIL. Strs Ohio acquired a new position in shares of Precision BioSciences during the 2nd quarter worth approximately $31,000. Ladenburg Thalmann Financial Services Inc. acquired a new stake in shares of Precision BioSciences in the 2nd quarter valued at approximately $33,000. Royal Bank of Canada bought a new position in shares of Precision BioSciences in the second quarter valued at $38,000. MUFG Americas Holdings Corp bought a new position in shares of Precision BioSciences in the second quarter valued at $51,000. Finally, IHT Wealth Management LLC acquired a new position in Precision BioSciences during the third quarter worth $93,000. Hedge funds and other institutional investors own 44.04% of the company’s stock.
About Precision BioSciences
Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.
Recommended Story: Are analyst ratings accurate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.